摘要
目的:了解上海地区医院调脂药的应用情况及趋势。方法:采用回顾性方法,对上海地区119家医院2010-2012年调脂药的品种、销售金额、用药频度(DDDs)、日均费用(DDC)等进行统计、分析。结果:各年度调脂药的总销售金额逐年增长,且增速逐年扩大;他汀类药物占调脂药市场的绝对主导地位,其后依次为中成药类和贝特类;2010-2011年销售金额排序列前3位的是阿托伐他汀、辛伐他汀和普伐他汀,2012年依次为阿托伐他汀、瑞舒伐他汀和辛伐他汀;2010-2011年DDDs排序列前3位的是阿托伐他汀、辛伐他汀和非诺贝特,2012年依次为阿托伐他汀、辛伐他汀和瑞舒伐他汀。结论:高效、安全、依从性好的他汀类药物成为调脂药中的优先选择药物,今后市场前景继续看好。
OBJECTIVE： To evaluate the status quo and tendency of the utilization of lipid modifying agents （LMAs） in hospi-tals of Shanghai. METHODS： By retrospective analysis, the utilization of LMAs in 119 hospitals of Shanghai area during 2010-- 2012 was analyzed statistically in respects of drug categories, consumption sum, DDDs and DDC. RESULTS： Total consumption sum of LMAs increased year by year in Shanghai during 2010--2012, with the growth rate going up. Statins occupied an absolute leading position in the market of LMAs, followed by Chinese patent medicines and fibrates. Atorvastatin, simvastatin and pravas tatin ranked the top 3 in the list of consumption sum during 2010--2011; and atorvastatin, rosuvastatin and simvastatin occupied the top 3 in 2012. Atorvastatin, simvastatin and fenofibrate ranked the top 3 in the list of DDDs during 2010--2011; and atorvas tatin, simvastatin and rosuvastatin occupied the top 3 in 2012. CONCLUSIONS： The statins with high efficiency, good safety and compliance continue to be the top choices in LMAs and their future market prospects will be optimistic.
出处
《中国药房》
CAS
CSCD
2014年第6期500-503,共4页
China Pharmacy
